N
Nuclidium
Setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer…
About Nuclidium
Nuclidium AG is a clinical-stage biotechnology company specializing in the development of copper-based radiopharmaceuticals. The firm is focused on creating a new standard in precision oncology by developing next-generation solutions for both the diagnosis and treatment of cancer, a concept known as theranostics.
Read full description
The company's platform is centered on the use of copper isotopes, specifically 61Cu for PET imaging (diagnosis) and 67Cu for therapy. This approach reportedly offers significant advantages, including higher absorption of the agent by tumors and safer radiation profiles for patients. Nuclidium is advancing a pipeline of these targeted radiopharmaceuticals and has announced positive Phase 1 results for its novel PET imaging agent, 61Cu-NuriPro.
The business model appears to be focused on research and development, advancing its product pipeline through clinical trials. To support this, the company engages in strategic partnerships, such as its collaboration with Guerbet, to further the development and potential commercialization of its targeted copper-based radiotheranostics. The company operates in the specialized and high-growth market of radiopharmaceuticals and precision oncology.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Basel, Switzerland
- Employees
- 33
- Open positions
- 1
- Dealroom signal
- 93.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Health Diagnostics, Biotech and Pharma, Woman Founder, Radiopharmaceuticals, Copper, Horizon Europe, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2026 | $31M | $476M | Bayern Kapital · NRW.BANK · Vives Partners · DeepTech & Climate Fonds | ↗ |
| SERIES BOther financing | Jul 2025 | $95M | $381M | European Investment Bank · NEVA SGR · Wellington Partners · Kurma Partners | ↗ |
Growth signals
Latest recorded traffic for Nuclidium is 3.1K monthly website visits, up 273.5% over the last three months. Nuclidium's team grew 32% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Commission
Series A11 investors entered at this stage
Turos Capital
Guerbet
European Investment Bank
NEVA SGR
Wellington Partners
Kurma Partners
Angelini Ventures
Bayern Kapital
NRW.BANK
Vives Partners
DeepTech & Climate Fonds
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nuclidium on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuclidium’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.